Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma Journal Article


Authors: McIntyre, C. A.; Cohen, N. A.; Goldman, D. A.; Gonen, M.; Sadot, E.; O'Reilly, E. M.; Varghese, A. M.; Yu, K. H.; Balachandran, V. P.; Soares, K. C.; D'Angelica, M. I.; Drebin, J. A.; Kingham, T. P.; Allen, P. J.; Wei, A. C.; Jarnagin, W. R.
Article Title: Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma
Abstract: Objectives: Patients with locally advanced pancreatic adenocarcinoma (PDAC) receive induction chemotherapy with or without radiation, with the goal of R0 resection and improving survival. Herein, we evaluate the outcomes of patients who presented with Stage III PDAC and received induction FOLFIRINOX. Methods: An institutional database was queried for consecutive patients who received induction FOLFIRINOX for locally unresectable PDAC between 2010 and 2016. Clinical and radiographic parameters were assessed pre- and posttreatment, and clinical outcomes were evaluated. Results: There were 200 patients who met the inclusion criteria. The median number of cycles of FOLFIRINOX was 8, 70% (n = 140) received radiation, and 18% (n = 36) underwent resection. Median overall survival (OS) in resected patients was 36 months (95% confidence interval [CI]: 24–56), and this group had improved OS compared to patients that did not undergo resection (hazard ratio (95% CI): 0.41 (0.26–0.64), p < 0.001). Patients (n = 112) who did not progress on induction therapy but remained unresectable had a median OS of 23.9 months (95% CI: 21.1–25.4). Conclusion: Nearly 20% of patients with locally advanced PDAC responded sufficiently to induction FOLFIRINOX to undergo resection, which was associated with improved OS compared to patients that did not undergo resection. Patients with stable disease who remain unresectable represent a group of patients with locally advanced PDAC who may benefit from optimization of additional nonoperative treatment. © 2021 Wiley Periodicals LLC
Keywords: adult; cancer survival; controlled study; treatment outcome; treatment response; aged; middle aged; cancer surgery; survival rate; major clinical study; overall survival; mortality; fluorouracil; advanced cancer; drug dose reduction; multimodality cancer therapy; antineoplastic agents; gemcitabine; cancer radiotherapy; combined modality therapy; pancreatic neoplasms; cancer staging; antineoplastic agent; cohort studies; tumor volume; antineoplastic combined chemotherapy protocols; clinical assessment; ca 19-9 antigen; carcinoembryonic antigen; carcinoma, pancreatic ductal; cohort analysis; pathology; data base; irinotecan; pancreas carcinoma; folinic acid; pancreas tumor; pancreatectomy; inoperable cancer; oxaliplatin; biliary tract drainage; leucovorin; fluoropyrimidine; induction chemotherapy; celiac artery; clinical outcome; pancreatic ductal carcinoma; humans; human; male; female; article; folfirinox
Journal Title: Journal of Surgical Oncology
Volume: 125
Issue: 3
ISSN: 0022-4790
Publisher: Wiley Blackwell  
Date Published: 2022-03-01
Start Page: 425
End Page: 436
Language: English
DOI: 10.1002/jso.26735
PUBMED: 34719035
PROVIDER: scopus
PMCID: PMC8933849
DOI/URL:
Notes: Article -- Export Date: 1 March 2022 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Mithat Gonen
    1029 Gonen
  2. Anna Mary Varghese
    145 Varghese
  3. Peter Allen
    501 Allen
  4. Kenneth Ho-Ming Yu
    163 Yu
  5. William R Jarnagin
    903 Jarnagin
  6. T Peter Kingham
    609 Kingham
  7. Eileen O'Reilly
    780 O'Reilly
  8. Debra Alyssa Goldman
    158 Goldman
  9. Noah Avram Cohen
    19 Cohen
  10. Jeffrey Adam Drebin
    165 Drebin
  11. Alice Chia-Chi Wei
    197 Wei
  12. Kevin Cerqueira Soares
    136 Soares